Biotherapeutic Research – ImmunoPrecise Antibodies Ltd.’s (NASDAQ: IPA) ($IPA) (“IPA”) interview with Dr. Jennifer Bath, CEO/President


From the Nasdaq MarketSite studio, New to The Street airs TV Host Jane King’s interview with Dr. Jennifer Bath, Chief Executive Officer and President of ImmunoPrecise Antibodies, Ltd. (NASDAQ: IPA) ($IPA) (“IPA”). IPA is a biotherapeutic research company that combines industry-leading antibody discovery services and complex artificial intelligence technologies. For about 30 years, the Company has helped create novel drug therapeutics and methods for oncology, inflammatory inflictions, and chronic and deadly diseases. Hundreds of companies have used IPA as their pharmaceutical partner in finding drug treatments. Dr. Bath talks about the Company’s BioStrand subsidiary and how it is advancing IPA’s existing platform in antibody AI-driven biotherapeutic research and technology. Finding new drug candidates to solve problems is often complex and, in some cases, impossible. Clients come to IPA because of its advanced AI platform and seek solutions that cannot be easily obtainable within their organization and labs. Dr. Bath gives an example of how the Company’s AI biotherapeutic platform targets tumors’ micron cellular levels. Tumors change in shape, molecular composures, and cellular Ph Levels within and around themselves. It is challenging to pinpoint the source of these molecular changes, so IPA is working with a client to develop and target tumor growth using the platform. The on-screen QR code is available during the show; download or visit ImmunoPrecise Antibodies, Ltd. (“IPA”) – The interview will air on Newsmax, episode 479, on June 17, 2023, at 3:30 PM ET, and the FOX Business Network, episode 480, on June 19, 2023, at 10:30 PM PT.

To make sure you never miss a video from New to the Street, click here to subscribe:

Follow New to the Street on Twitter:

Follow New to the Street on Facebook:

Follow New to the Street on Instagram:

Follow New to the Street on Rumble:

About New to the Street:

Subscribe to our Mailing List: